| 产品描述: | PDGFRβ 选择性抑制剂;PDGFRβ Selective Inhibitors;;InformationAZD3229 is a potent, pan-Kit (c-Kit) mutantinhibitor with potent single digit nM growth inhibition against a diverse panel of mutant Kit (c-Kit) driven Ba/F3 cell lines (GI50=1-50 nM), with good margin to KDR-driven effects. It also inhibitsPDGFR mutants(Tel-PDGFRα, Tel-PDGFRβ, V561D/D842V).TargetsKit ; PDGFRα ; PDGFRβIn vivoIn preclinical species, bioavailability is high and clearance low across all of mouse, rat, and dog. Volume of distribution is low consistent with the neutral structure. In in vivo models using Ba/F3 cell lines, AZD3229 at a dose of 20 mg/kg b.i.d induces tumor volume regression more effectively than regorafenib at a dose of 100 mg/kg q.d and imatinib. |
| 靶点: |
IC50: 223.3 nM (c-Kit) |
| 参考文献: |
1. Ryu H, et.al. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells. Int J Mol Sci. 2019 Sep 24;20(19):4728. 2. Kettle JG, et al. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy) quinazolin-4-yl]amino} phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797-8810. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.085 ml |
10.427 ml |
20.855 ml |
| 5 mM |
0.417 ml |
2.085 ml |
4.171 ml |
| 10 mM |
0.209 ml |
1.043 ml |
2.085 ml |
| 50 mM |
0.042 ml |
0.209 ml |
0.417 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |